ATE85622T1 - Chimarenglykoproteine, enthaltend immunogene segmente des humanen respiratorischen synzytialvirus. - Google Patents

Chimarenglykoproteine, enthaltend immunogene segmente des humanen respiratorischen synzytialvirus.

Info

Publication number
ATE85622T1
ATE85622T1 AT88909879T AT88909879T ATE85622T1 AT E85622 T1 ATE85622 T1 AT E85622T1 AT 88909879 T AT88909879 T AT 88909879T AT 88909879 T AT88909879 T AT 88909879T AT E85622 T1 ATE85622 T1 AT E85622T1
Authority
AT
Austria
Prior art keywords
respiratory syncytial
syncytial virus
human respiratory
glycoproteins
containing immunogenic
Prior art date
Application number
AT88909879T
Other languages
English (en)
Inventor
Michael Wathen
Original Assignee
Upjohn Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Upjohn Co filed Critical Upjohn Co
Application granted granted Critical
Publication of ATE85622T1 publication Critical patent/ATE85622T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18522—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT88909879T 1987-12-23 1988-10-31 Chimarenglykoproteine, enthaltend immunogene segmente des humanen respiratorischen synzytialvirus. ATE85622T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US13738787A 1987-12-23 1987-12-23
PCT/US1988/003784 WO1989005823A1 (en) 1987-12-23 1988-10-31 Chimeric glycoproteins containing immunogenic segments of the glycoproteins of human respiratory syncytial virus
EP88909879A EP0396563B1 (de) 1987-12-23 1988-10-31 Chimarenglykoproteine, enthaltend immunogene segmente des humanen respiratorischen synzytialvirus

Publications (1)

Publication Number Publication Date
ATE85622T1 true ATE85622T1 (de) 1993-02-15

Family

ID=22477194

Family Applications (1)

Application Number Title Priority Date Filing Date
AT88909879T ATE85622T1 (de) 1987-12-23 1988-10-31 Chimarenglykoproteine, enthaltend immunogene segmente des humanen respiratorischen synzytialvirus.

Country Status (14)

Country Link
US (2) US5194595A (de)
EP (1) EP0396563B1 (de)
JP (1) JP2716503B2 (de)
KR (1) KR0137963B1 (de)
AT (1) ATE85622T1 (de)
AU (1) AU617739B2 (de)
CA (1) CA1320163C (de)
DE (1) DE3878468T2 (de)
DK (1) DK173175B1 (de)
FI (1) FI102382B (de)
HK (1) HK166295A (de)
MX (1) MX9203458A (de)
NO (1) NO300254B1 (de)
WO (1) WO1989005823A1 (de)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8914968D0 (en) * 1989-06-29 1989-08-23 Connaught Lab Production of virus and purification of viral envelope proteins for vaccine use
US6004563A (en) * 1990-11-07 1999-12-21 American Home Products Corporation Feline vaccine compositions and method for preventing chlamydia infections or diseases using the same
US5824307A (en) * 1991-12-23 1998-10-20 Medimmune, Inc. Human-murine chimeric antibodies against respiratory syncytial virus
GB9200117D0 (en) * 1992-01-06 1992-02-26 Connaught Lab Production of recombinant chimeric proteins for vaccine use
GB9207479D0 (en) * 1992-04-06 1992-05-20 Scotgen Ltd Novel antibodies for treatment and prevention of respiratory syncytial virus infection in animals and man
TW275632B (de) * 1992-04-21 1996-05-11 American Cyanamid Co
WO1994015968A1 (en) * 1993-01-08 1994-07-21 The Upjohn Company Process for the purification and refolding of human respiratory syncytial virus fg glycoprotein
RU2160119C2 (ru) * 1993-05-25 2000-12-10 Американ Цианамид Компани Вакцинная композиция, содержащая белок респираторно-синцитиального вируса (варианты)
US7300918B2 (en) 1994-01-14 2007-11-27 Matthias Rath Method of producing vaccines from protein signal oligopeptides
ATE291230T1 (de) * 1994-01-14 2005-04-15 Matthias Dr Med Rath Verwendung von methoden zur identifizierung von hydrophilen signal-oligopeptiden
FR2718452B1 (fr) 1994-04-06 1996-06-28 Pf Medicament Elément d'immunogène, agent immunogène, composition pharmaceutique et procédé de préparation.
WO1996010400A1 (en) * 1994-09-30 1996-04-11 The Uab Research Foundation Gene therapy vectors and vaccines based on non-segmented negatives stranded rna viruses
US5716821A (en) * 1994-09-30 1998-02-10 Uab Research Foundation Prevention and treatment of respiratory tract disease
FR2726472B1 (fr) 1994-11-07 1997-01-31 Pf Medicament Proteine porteuse a effet adjuvant, complexe immunogene la contenant, leur procede de preparation, sequence nucleotidique et vaccin
DE4442114A1 (de) * 1994-11-25 1996-05-30 Buna Sow Leuna Olefinverb Gmbh Nitrit-, phosphat- und aminfreies Kühl- und Wärmeübertragungsmittel
US5811524A (en) * 1995-06-07 1998-09-22 Idec Pharmaceuticals Corporation Neutralizing high affinity human monoclonal antibodies specific to RSV F-protein and methods for their manufacture and therapeutic use thereof
US6015664A (en) * 1995-11-03 2000-01-18 Mcw Research Foundation Multiplex PCR assay using unequal primer concentrations to detect HPIV 1,2,3 and RSV A,B and influenza virus A, B
WO1998018819A1 (en) * 1996-10-29 1998-05-07 Smithkline Beecham Biologicals S.A. Purification of respiratory syncytial virus antigens
WO1999002667A1 (en) * 1997-07-14 1999-01-21 University Of Liege Mutations in the myostation gene cause double-muscling in mammals
US20070067859A1 (en) * 1997-07-14 2007-03-22 Michel Georges Double-muscling in mammals
US6103466A (en) * 1997-07-14 2000-08-15 University Of Liege Double-muscling in mammals
US6699478B1 (en) * 1997-09-19 2004-03-02 Wyeth Holdings Corporation Enhanced immune response to attachment (G) protein of Respiratory Syncytial Virus
GB9909077D0 (en) 1999-04-20 1999-06-16 Smithkline Beecham Biolog Novel compositions
CA2398466A1 (en) * 2000-01-27 2001-08-02 Medimmune, Inc. Ultra high affinity neutralizing antibodies
JP2003525061A (ja) 2000-03-01 2003-08-26 メディミューン，インコーポレイテッド 高効力組換え抗体およびその産生法
US7179900B2 (en) * 2000-11-28 2007-02-20 Medimmune, Inc. Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment
US6855493B2 (en) 2000-11-28 2005-02-15 Medimmune, Inc. Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment
US7132100B2 (en) * 2002-06-14 2006-11-07 Medimmune, Inc. Stabilized liquid anti-RSV antibody formulations
US20080113015A1 (en) * 2004-05-24 2008-05-15 Polymun Scientific Immunbiologische Forschung Gmbh Superloaded Liposomes for Drug Delivery
CA2585891A1 (en) * 2004-10-29 2006-05-11 Medimmune, Inc. Methods of preventing and treating rsv infections and related conditions
EP1997830A1 (de) 2007-06-01 2008-12-03 AIMM Therapeutics B.V. RSV-spezifische Bindemoleküle und Mittel zu ihrer Herstellung
US8563002B2 (en) 2007-12-24 2013-10-22 Glaxosmithkline Biologicals, S.A. Recombinant RSV antigens
KR20110045008A (ko) * 2008-07-18 2011-05-03 아이디 바이오메디컬 코포레이션 오브 퀘벡 키메라 호흡기 세포융합 바이러스 폴리펩티드 항원
PL2445526T3 (pl) 2009-06-24 2017-08-31 Glaxosmithkline Biologicals S.A. Rekombinowane antygeny rsv
EP4183412B1 (de) 2009-07-15 2024-08-14 GlaxoSmithKline Biologicals SA Rsv-f-proteinzusammensetzungen und verfahren zu ihrer herstellung
US8568726B2 (en) 2009-10-06 2013-10-29 Medimmune Limited RSV specific binding molecule
RS56748B1 (sr) 2011-05-13 2018-03-30 Glaxosmithkline Biologicals Sa Pre-fuzioni rsv f antigeni
SI2879702T1 (sl) 2012-08-01 2020-02-28 Bavarian Nordic A/S Cepivo na osnovi rekombinantnega modificiranega virusa vakcinacije Ankara (MVA) proti respiratornemu sincitialnemu virusu (RSV)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4855224A (en) * 1984-03-09 1989-08-08 Genentech, Inc. Molecularly cloned diagnostic product and method of use
DE3689622T2 (de) * 1986-01-14 1994-06-16 Univ North Carolina Impfstoffe gegen menschliche respiratorische viren.
US5223254A (en) * 1987-09-29 1993-06-29 Praxis Biologics, Inc. Respiratory syncytial virus: vaccines
US5001230A (en) * 1988-02-18 1991-03-19 Schering Corporation T cell activation markers
SG106639A1 (en) * 2000-10-10 2004-10-29 Gen Electric Apparatus and method for introducing small amounts of refractory elements into a vapor deposition coating

Also Published As

Publication number Publication date
KR0137963B1 (ko) 1998-04-30
NO902802D0 (no) 1990-06-22
NO300254B1 (no) 1997-05-05
FI102382B1 (fi) 1998-11-30
FI102382B (fi) 1998-11-30
EP0396563B1 (de) 1993-02-10
DK153290A (da) 1990-08-16
DK153290D0 (da) 1990-06-22
HK166295A (en) 1995-11-03
EP0396563A1 (de) 1990-11-14
DK173175B1 (da) 2000-03-06
JP2716503B2 (ja) 1998-02-18
DE3878468T2 (de) 1993-06-09
JPH03501723A (ja) 1991-04-18
NO902802L (no) 1990-06-22
US5288630A (en) 1994-02-22
FI903154A0 (fi) 1990-06-21
DE3878468D1 (de) 1993-03-25
AU617739B2 (en) 1991-12-05
US5194595A (en) 1993-03-16
KR900700508A (ko) 1990-08-13
CA1320163C (en) 1993-07-13
MX9203458A (es) 1992-09-01
AU2785089A (en) 1989-07-19
WO1989005823A1 (en) 1989-06-29

Similar Documents

Publication Publication Date Title
DE3878468D1 (de) Chimarenglykoproteine, enthaltend immunogene segmente des humanen respiratorischen synzytialvirus.
NO904538D0 (no) Kimaere glykoproteiner inneholdende immunogene segmenter av humant parainfluensavirus type 3.
ES8203226A1 (es) Procedimiento de preparar complejos vacunantes por reaccion de arn ribonosales y de antigenos especificos.
BR1101088A (pt) Proteìna g do vìrus sincicial respiratório não glicosilada isolada e substancialmente pura
EE9900343A (et) Sünteetiline polünukleotiid, immuunvastuste tekitamise meetod, immunogeenne kompositsioon, anti-HIV immuunvastuste indutseerimise meetod, meetod antigeeni tekitava raku indutseerimiseks ja farmatseutiline kompositsioon
KR890701758A (ko) 재조합 dna에서 유도한 보르데텔라 외독소 소단위체의 유사체 및 그를 포함하는 백신
DE60041280D1 (de) Chimäre mensch-rinder respiratory syncytial virus vakzinen
CA2231603A1 (en) Chicken interleukin-15 and uses thereof
ATE101200T1 (de) Impfstoffe gegen menschliche respiratorische viren.
MXPA01013302A (es) Vacunas para el virus de la parainfluenza (piv) quimerico para humanos-bovinos atenuadas.
DE69836520D1 (de) Clostridium perfringens Impfstoff
EP0556333A4 (de) Avirulente mikroben und ihre verwendung: salmonella typhi.
ES2130189T3 (es) Vacunas de virus sincitial respiratorio (rsv) mutante que contienen dicho virus y procedimientos de uso.
MY101874A (en) Vaccine
DK8789A (da) Fremgangsmaade til fremstilling af modificerede, staerkt afsvaekkede rna-virusstammer samt vaccine og dens anvendelse
YU49995A (sh) Polinukleotidna vakcina za virus herpesa
EP0186368A3 (en) Biological preparations
AU3970099A (en) Avian polyomavirus vaccines in psittacine birds
DK230890A (da) Dna-fragment, der koder for et pasteurella multocida-toxin eller for en subsekvens eller analog deraf, ekspressionsvektor, der omfatter dna-fragmentet, mikroorganisme, der udtrykker dette, fremgangsmaade til fremstilling af et pasteurella-multocida-toxin, diagnostisk middel samt anvendelse heraf, vaccine indeholdende et pasteurella-multocida-toxinderivat, anvendelse af pasteurella multocida-t m.m.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
EELA Cancelled due to lapse of time